Medilines sets ₱2.30 per share for IPO | Inquirer Business

Medilines sets ₱2.30 per share for IPO

/ 10:23 AM November 17, 2021

Photo from Medilines Website

MANILA, Philippines—Medical equipment distributor Medilines Distributors Inc. priced its initial public offering at P2.30 per share, finalizing the size of its stock market debut at close to P1.9 billion.

This marked a 6.12 discount from the P2.45 maximum offering price earlier indicated by the company, which is positioning itself as the first health-care pure player in the stock market.


Medilines is set to offer up to 550 million primary shares and up to 275 million secondary shares from November 22 to 26 this year, bringing 30 percent of its shares to public hands.

Tentative listing on the main board of the PSE under the ticker “MEDIC” is scheduled on Dec. 7.


Medilines is led by businessman Virgilio Villar, brother of real estate tycoon Manuel Villar Jr.

Proceeds from the offer will be used to finance Medilines’ working capital in relation to the procurement of existing products and the build-up of its medical consumables inventory, while the rest will be used to repay debt.

Founded in 2002, Medilines distributes medical equipment to both public and private healthcare facilities in the Philippines. Its portfolio, which includes equipment from multinational medical device companies, primarily caters to specialized medicine, including diagnostic imaging, dialysis and cancer therapy.


Subscribe to our business newsletter

By providing an email address. I agree to the Terms of Use and acknowledge that I have read the Privacy Policy.
Read Next
Don't miss out on the latest news and information.

Subscribe to INQUIRER PLUS to get access to The Philippine Daily Inquirer & other 70+ titles, share up to 5 gadgets, listen to the news, download as early as 4am & share articles on social media. Call 896 6000.

TAGS: IPO, medical equipment, Mediline, Virgilio Villar
For feedback, complaints, or inquiries, contact us.

Subscribe to our business news

By providing an email address. I agree to the Terms of Use and
acknowledge that I have read the Privacy Policy.

© Copyright 1997-2022 | All Rights Reserved

We use cookies to ensure you get the best experience on our website. By continuing, you are agreeing to our use of cookies. To find out more, please click this link.